ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) Stock Price Up 1.8% – Time to Buy?

ALPS Medical Breakthroughs ETF (NYSEARCA:SBIO) rose 1.8% during trading on Thursday . The company traded as high as $53.88 and last traded at $53.80. Approximately 19,145 shares traded hands during trading, a decline of 48% from the average daily volume of 36,471 shares. The stock had previously closed at $52.83.

ALPS Medical Breakthroughs ETF Trading Up 1.8%

The business’s 50-day simple moving average is $53.12 and its 200 day simple moving average is $51.14.

Institutional Trading of ALPS Medical Breakthroughs ETF

A number of institutional investors have recently modified their holdings of the company. Delta Investment Management LLC bought a new stake in shares of ALPS Medical Breakthroughs ETF in the 4th quarter valued at about $6,112,000. Bank of America Corp DE boosted its holdings in shares of ALPS Medical Breakthroughs ETF by 63.1% in the 1st quarter. Bank of America Corp DE now owns 98,679 shares of the company’s stock valued at $5,165,000 after buying an additional 38,193 shares in the last quarter. LPL Financial LLC boosted its holdings in shares of ALPS Medical Breakthroughs ETF by 438.7% in the 4th quarter. LPL Financial LLC now owns 42,755 shares of the company’s stock valued at $2,190,000 after buying an additional 34,819 shares in the last quarter. Griffin Asset Management Inc. boosted its holdings in shares of ALPS Medical Breakthroughs ETF by 1.9% in the 4th quarter. Griffin Asset Management Inc. now owns 30,699 shares of the company’s stock valued at $1,572,000 after buying an additional 564 shares in the last quarter. Finally, Moran Wealth Management LLC boosted its holdings in shares of ALPS Medical Breakthroughs ETF by 39.2% in the 1st quarter. Moran Wealth Management LLC now owns 29,348 shares of the company’s stock valued at $1,536,000 after buying an additional 8,264 shares in the last quarter.

ALPS Medical Breakthroughs ETF Company Profile

The ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is managed by ALPS.